Haohong (Qihe) Pharmaceutical Technology Co., Ltd. is located in the High-tech Zone of Qihe County, Shandong Province, adjacent to the Yellow River and within the Jinan Economic Circle, enjoying convenient transportation. The company specializes in the R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It passed the ISO 9001:2015 quality management system certification in 2021, was recognized as a Technology-based Small and Medium-sized Enterprise in 2024, and awarded Innovative Small and Medium-sized Enterprise of Shandong Province in 2025. Haohong has a high-level R&D team and a full range of analytical testing instruments and methods. At present, its production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors, with an annual production capacity of 1,000 tons. The company focuses on the development of active pharmaceutical ingredients and intermediates for anti-cancer, anti-hepatitis C and anti-diabetic therapies, with an emphasis on high-grade intermediates. Its main products include Bicalutamide, Enzalutamide, Apalutamide, Darolutamide, Abemaciclib, Venetoclax, Macitentan, Empagliflozin, Larotrectinib, Apixaban, Rivaroxaban, Ibrutinib, Ceritinib, Pomalidomide, Lenalidomide, Ivacaftor, Tofacitinib, Cabozantinib, Alectinib, etc. Our products are exported to overseas markets including the United States, Europe, Japan, India, Bangladesh and other regions. The company currently has dozens of high-grade intermediates available for commercial production, and also provides customers with efficient custom synthesis services ranging from gram scale to hundreds of kilograms. Adhering to the corporate philosophy of "Pragmatism, Innovation, Integrity", Haohong is committed to serving global customers with full dedication!

Haohong (Qihe) Pharmaceutical Technology Co., Ltd. is located in the High-tech Zone of Qihe County, Shandong Province, adjacent to the Yellow River and within the Jinan Economic Circle, enjoying convenient transportation. The company specializes in the R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It passed the ISO 9001:2015 quality management system certification in 2021, was recognized as a Technology-based Small and Medium-sized Enterprise in 2024, and awarded Innovative Small and Medium-sized Enterprise of Shandong Province in 2025. Haohong has a high-level R&D team and a full range of analytical testing instruments and methods. At present, its production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors, with an annual production capacity of 1,000 tons. The company focuses on the development of active pharmaceutical ingredients and intermediates for anti-cancer, anti-hepatitis C and anti-diabetic therapies, with an emphasis on high-grade intermediates. Its main products include Bicalutamide, Enzalutamide, Apalutamide, Darolutamide, Abemaciclib, Venetoclax, Macitentan, Empagliflozin, Larotrectinib, Apixaban, Rivaroxaban, Ibrutinib, Ceritinib, Pomalidomide, Lenalidomide, Ivacaftor, Tofacitinib, Cabozantinib, Alectinib, etc. Our products are exported to overseas markets including the United States, Europe, Japan, India, Bangladesh and other regions. The company currently has dozens of high-grade intermediates available for commercial production, and also provides customers with efficient custom synthesis services ranging from gram scale to hundreds of kilograms. Adhering to the corporate philosophy of "Pragmatism, Innovation, Integrity", Haohong is committed to serving global customers with full dedication!

Haohong (Qihe) Pharmaceutical Technology Co., Ltd. is located in the High-tech Zone of Qihe County, Shandong Province, adjacent to the Yellow River and within the Jinan Economic Circle, enjoying convenient transportation. The company specializes in the R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It passed the ISO 9001:2015 quality management system certification in 2021, was recognized as a Technology-based Small and Medium-sized Enterprise in 2024, and awarded Innovative Small and Medium-sized Enterprise of Shandong Province in 2025. Haohong has a high-level R&D team and a full range of analytical testing instruments and methods. At present, its production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors, with an annual production capacity of 1,000 tons. The company focuses on the development of active pharmaceutical ingredients and intermediates for anti-cancer, anti-hepatitis C and anti-diabetic therapies, with an emphasis on high-grade intermediates. Its main products include Bicalutamide, Enzalutamide, Apalutamide, Darolutamide, Abemaciclib, Venetoclax, Macitentan, Empagliflozin, Larotrectinib, Apixaban, Rivaroxaban, Ibrutinib, Ceritinib, Pomalidomide, Lenalidomide, Ivacaftor, Tofacitinib, Cabozantinib, Alectinib, etc. Our products are exported to overseas markets including the United States, Europe, Japan, India, Bangladesh and other regions. The company currently has dozens of high-grade intermediates available for commercial production, and also provides customers with efficient custom synthesis services ranging from gram scale to hundreds of kilograms. Adhering to the corporate philosophy of "Pragmatism, Innovation, Integrity", Haohong is committed to serving global customers with full dedication!

Haohong (Qihe) Pharmaceutical Technology Co., Ltd. is located in the High-tech Zone of Qihe County, Shandong Province, adjacent to the Yellow River and within the Jinan Economic Circle, enjoying convenient transportation. The company specializes in the R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It passed the ISO 9001:2015 quality management system certification in 2021, was recognized as a Technology-based Small and Medium-sized Enterprise in 2024, and awarded Innovative Small and Medium-sized Enterprise of Shandong Province in 2025. Haohong has a high-level R&D team and a full range of analytical testing instruments and methods. At present, its production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors, with an annual production capacity of 1,000 tons. The company focuses on the development of active pharmaceutical ingredients and intermediates for anti-cancer, anti-hepatitis C and anti-diabetic therapies, with an emphasis on high-grade intermediates. Its main products include Bicalutamide, Enzalutamide, Apalutamide, Darolutamide, Abemaciclib, Venetoclax, Macitentan, Empagliflozin, Larotrectinib, Apixaban, Rivaroxaban, Ibrutinib, Ceritinib, Pomalidomide, Lenalidomide, Ivacaftor, Tofacitinib, Cabozantinib, Alectinib, etc. Our products are exported to overseas markets including the United States, Europe, Japan, India, Bangladesh and other regions. The company currently has dozens of high-grade intermediates available for commercial production, and also provides customers with efficient custom synthesis services ranging from gram scale to hundreds of kilograms. Adhering to the corporate philosophy of "Pragmatism, Innovation, Integrity", Haohong is committed to serving global customers with full dedication!